دورية أكاديمية
أعرض في EDS

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

التفاصيل البيبلوغرافية
العنوان: G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
المؤلفون: Martinez Sanz P; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands p.martinezsanz@sanquin.nl., van Rees DJ; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., van Zogchel LMJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands., Klein B; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Bouti P; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Olsman H; Laboratory for Immunotherapy, Sanquin Research, Amsterdam, The Netherlands., Schornagel K; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Kok I; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Sunak A; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Leeuwenburg K; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Timmerman I; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands., Dierselhuis MP; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kholosy WM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., van Bruggen R; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., van den Berg TK; Laboratory for Immunotherapy, Sanquin Research, Amsterdam, The Netherlands.; Department of Molecular Cell Biology and Immunology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Kuijpers TW; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.; Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital UMC, Amsterdam, The Netherlands., Matlung HL; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Tytgat GAM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Franke K; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.
المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 May; Vol. 9 (5).
نوع المنشور: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : London, United Kingdom : BMJ Publishing Group Ltd.
Original Publication: London : BioMed Central, 2013-
مواضيع طبية MeSH: Adjuvants, Immunologic/*pharmacology , Antibodies, Monoclonal/*pharmacology , Antineoplastic Agents, Immunological/*pharmacology , Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Cytotoxicity, Immunologic/*drug effects , Granulocyte Colony-Stimulating Factor/*pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology , Neuroblastoma/*drug therapy , Neutrophils/*drug effects, CD11b Antigen/metabolism ; CD18 Antigens/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Coculture Techniques ; Humans ; Neuroblastoma/immunology ; Neuroblastoma/metabolism ; Neuroblastoma/pathology ; Neutrophils/immunology ; Neutrophils/metabolism ; Neutrophils/pathology ; Receptors, IgG/metabolism ; Trogocytosis/drug effects ; Tumor Microenvironment
مستخلص: Background: Current immunotherapy for patients with high-risk neuroblastoma involves the therapeutic antibody dinutuximab that targets GD2, a ganglioside expressed on the majority of neuroblastoma tumors. Opsonized tumor cells are killed through antibody-dependent cellular cytotoxicity (ADCC), a process mediated by various immune cells, including neutrophils. The capacity of neutrophils to kill dinutuximab-opsonized tumor cells can be further enhanced by granulocyte-macrophage colony-stimulating factor (GM-CSF), which has been shown in the past to improve responses to anti-GD2 immunotherapy. However, access to GM-CSF (sargramostim) is limited outside of Northern America, creating a high clinical need for an alternative method to stimulate dinutuximab responsiveness in the treatment of neuroblastoma. In this in vitro study, we have investigated whether clinically well-established granulocyte colony-stimulating factor (G-CSF) can be a potentially suitable alternative for GM-CSF in the dinutuximab immunotherapy regimen of patients with neuroblastoma.
Methods: We compared the capacity of neutrophils stimulated either in vitro or in vivo with GM-CSF or G-CSF to kill dinutuximab-opsonized GD2-positive neuroblastoma cell lines and primary patient tumor material. Blocking experiments with antibodies inhibiting either respective Fc gamma receptors (FcγR) or neutrophil integrin CD11b/CD18 demonstrated the involvement of these receptors in the process of ADCC. Flow cytometry and live cell microscopy were used to quantify and visualize neutrophil-neuroblastoma interactions.
Results: We found that G-CSF was as potent as GM-CSF in enhancing the killing capacity of neutrophils towards neuroblastoma cells. This was observed with in vitro stimulated neutrophils, and with in vivo stimulated neutrophils from both patients with neuroblastoma and healthy donors. Enhanced killing due to GM-CSF or G-CSF stimulation was consistent regardless of dinutuximab concentration, tumor-to-neutrophil ratio and concentration of the stimulating cytokine. Both GM-CSF and G-CSF stimulated neutrophils required FcγRIIa and CD11b/CD18 integrin to perform ADCC, and this was accompanied by trogocytosis of tumor material by neutrophils and tumor cell death in both stimulation conditions.
Conclusions: Our preclinical data support the use of G-CSF as an alternative stimulating cytokine to GM-CSF in the treatment of high-risk neuroblastoma with dinutuximab, warranting further testing of G-CSF in a clinical setting.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
التعليقات: Comment in: J Immunother Cancer. 2021 Dec;9(12):. (PMID: 34893525)
References: Front Immunol. 2019 Jan 30;9:3124. (PMID: 30761158)
Blood. 1995 Aug 1;86(3):1124-30. (PMID: 7542496)
Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567. (PMID: 28389455)
Blood. 1991 Aug 15;78(4):1105-11. (PMID: 1907873)
Nat Rev Cancer. 2002 Jun;2(6):442-54. (PMID: 12189386)
Cancer Immunol Res. 2021 Feb;9(2):147-155. (PMID: 33355195)
Int J Oncol. 2002 Sep;21(3):649-54. (PMID: 12168113)
Immunol Rev. 2016 Sep;273(1):312-28. (PMID: 27558343)
Pharmacotherapy. 2003 Aug;23(8 Pt 2):9S-14S. (PMID: 12921217)
Mol Cancer Ther. 2016 Aug;15(8):1879-89. (PMID: 27226489)
Lancet Oncol. 2018 Dec;19(12):1617-1629. (PMID: 30442501)
Immunol Rev. 2015 Nov;268(1):25-51. (PMID: 26497511)
J Pediatr Hematol Oncol. 2021 Apr 1;43(3):e358-e364. (PMID: 31815885)
Blood. 1991 Aug 15;78(4):885-9. (PMID: 1714327)
Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. (PMID: 29949776)
Biologics. 2018 Dec 21;13:1-12. (PMID: 30613134)
Eur J Immunol. 2002 May;32(5):1502-8. (PMID: 11981839)
J Clin Invest. 2005 Aug;115(8):2083-98. (PMID: 16007267)
Nat Genet. 2017 Aug;49(8):1261-1266. (PMID: 28650485)
Ann Oncol. 2003 Jan;14(1):29-35. (PMID: 12488289)
Blood. 2008 Sep 15;112(6):2390-9. (PMID: 18566325)
J Clin Oncol. 2008 Nov 20;26(33):5443-9. (PMID: 18838715)
Cancer Res. 1990 Sep 1;50(17):5234-9. (PMID: 2386933)
Expert Rev Anticancer Ther. 2017 Apr;17(4):369-386. (PMID: 28142287)
Pediatr Blood Cancer. 2009 Sep;53(3):375-8. (PMID: 19484756)
Eur J Cancer. 2014 Feb;50(3):628-37. (PMID: 24321263)
Blood. 2002 Jun 1;99(11):4166-73. (PMID: 12010822)
Cells. 2020 Dec 08;9(12):. (PMID: 33302385)
Cancers (Basel). 2021 Jan 05;13(1):. (PMID: 33466359)
Cancer Res. 2015 Sep 15;75(18):3991. (PMID: 26337906)
Clin Chem. 2009 Jul;55(7):1316-26. (PMID: 19460840)
Haematologica. 1997 Sep-Oct;82(5):606-16. (PMID: 9407734)
Cancer Res. 2013 Jul 1;73(13):4134-46. (PMID: 23687340)
Dev Cell. 2008 Jun;14(6):818-29. (PMID: 18539112)
Cancer Res. 2015 Jun 15;75(12):2566-79. (PMID: 25908586)
JCO Precis Oncol. 2019 Oct 03;3:. (PMID: 34036221)
J Pediatr Hematol Oncol. 2005 Aug;27(8):449-51. (PMID: 16096530)
Cell Tissue Res. 2018 May;372(2):233-243. (PMID: 28924803)
J Pediatr Surg. 2008 May;43(5):837-42. (PMID: 18485949)
Trends Cancer. 2017 Feb;3(2):149-160. (PMID: 28718445)
Lancet. 2007 Jun 23;369(9579):2106-20. (PMID: 17586306)
FEBS Lett. 2014 Jan 21;588(2):288-97. (PMID: 24295643)
N Engl J Med. 2010 Sep 30;363(14):1324-34. (PMID: 20879881)
Cancer Res. 1991 Jan 1;51(1):144-9. (PMID: 1988079)
Blood. 1989 May 15;73(7):1936-41. (PMID: 2653466)
J Clin Oncol. 2010 Jul 20;28(21):3516-24. (PMID: 20567002)
J Clin Oncol. 2012 Feb 1;30(4):426-32. (PMID: 22203761)
Children (Basel). 2018 Aug 28;5(9):. (PMID: 30154341)
J Clin Oncol. 2009 Jan 1;27(1):85-91. (PMID: 19047298)
Pediatr Blood Cancer. 2013 Jun;60(6):985-93. (PMID: 23255319)
فهرسة مساهمة: Keywords: cytokines; cytotoxicity; immunity; immunologic; immunotherapy; innate; neuroblastoma
المشرفين على المادة: 0 (Adjuvants, Immunologic)
0 (Antibodies, Monoclonal)
0 (Antineoplastic Agents, Immunological)
0 (CD11b Antigen)
0 (CD18 Antigens)
0 (FCGR2A protein, human)
0 (ITGAM protein, human)
0 (Receptors, IgG)
143011-72-7 (Granulocyte Colony-Stimulating Factor)
7SQY4ZUD30 (dinutuximab)
83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
تواريخ الأحداث: Date Created: 20210529 Date Completed: 20220105 Latest Revision: 20220105
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8166600
DOI: 10.1136/jitc-2020-002259
PMID: 34049929
قاعدة البيانات: MEDLINE
الوصف
تدمد:2051-1426
DOI:10.1136/jitc-2020-002259